Threshold is also conducting a phase III study of TH-302 in soft tissue sarcoma, with interim results expected by the end of the year.
If you're interested in a sarcoma drug stock that hasn't yet had a big run, take a look at Ziopharm (ZIOP) and its drug palifosfamide. Data from a phase III study are expected in the second half of the year.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein.
>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.>To submit a news tip, send an email to: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.